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ABSTRACT
Hepatocellular carcinoma (HCC) results from accumulation of both genetic and 
epigenetic alterations. We investigated the genome-wide DNA methylation profile 
in 69 pairs of HCC and adjacent non-cancerous liver tissues using the Infinium 
HumanMethylation 450K BeadChip array. An innovative analytical approach has been 
adopted to identify Stochastic Epigenetic Mutations (SEMs) in HCC.
HCC and peritumoral tissues showed a different epigenetic profile, mainly 
characterized by loss of DNA methylation in HCC. Total number of SEMs was 
significantly higher in HCC tumor (median: 77,370) than in peritumoral (median: 
5,656) tissues and correlated with tumor grade. A significant positive association 
emerged between SEMs measured in peritumoral tissue and hepatitis B and/or C virus 
infection status. A restricted number of SEMs resulted to be shared by more than 90% 
of HCC tumor samples and never present in peritumoral tissue. This analysis allowed 
the identification of four epigenetically regulated candidate genes (AJAP1, ADARB2, 
PTPRN2, SDK1), potentially involved in the pathogenesis of HCC.
In conclusion, HCC showed a methylation profile completely deregulated and very 
far from adjacent non-cancerous liver tissues. The SEM analysis provided valuable 
clues for further investigations in understanding the process of tumorigenesis in HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a common 
cancers and the second leading cause of cancer-related 
death among males in the world [1]. Indeed, advanced 
HCC not eligible for local therapies has limited chances 
of cure [2], notwithstanding a massive effort in identifying 
novel therapeutic targets and predictive markers [3–5]. 
The pathogenesis of HCC is multifactorial and includes 
several extrinsic and intrinsic factors. Chronic liver 
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damage secondary to viral hepatitis, alcohol abuse or 
non-alcoholic steatohepatitis, represents the most critical 
determinant in the development of this tumor. Several 
recent studies have provided relevant insights in this 
field through the characterization of HCC by using whole 
genome/exome sequencing, genome-wide methylation 
arrays and RNA sequencing [6–8]. Although it is known 
that HCC results from accumulation of both genetic and 
epigenetic alterations, the molecular pathogenesis of this 
tumor is still not completely understood. Indeed, HCC is a 
complex and heterogeneous disease [9].
DNA methylation is one of the most widely 
characterized epigenetic modifications implicated in 
cancer development. Several studies evaluated the DNA 
methylation profile in HCC through genome-wide arrays 
[10–14]. Most of these reports compared the mean 
methylation level calculated for each CpG site in human 
HCC with that in adjacent non-cancerous liver tissue, 
and correlated the tumor methylation profile with clinical 
and pathological parameters in order to obtain a deeper 
understanding of the pathogenesis of this tumor. While this 
approach allows to identify epigenetic alterations shared 
by a group of subjects and potentially associated with their 
phenotype, rare or stochastic epigenetic alterations, that 
are not shared among subjects and minimally affect the 
mean methylation level of the group, remain unexplored, 
although they may play a role in hepatocarcinogenesis. In 
addition, an analytical strategy based on comparisons of 
mean methylation values does not allow to process data 
obtained from a single subject [15]. 
Epigenetic mutations, or the more common term 
“epimutations” are heritable changes in gene activity not 
associated with a DNA mutation but rather with gain or 
loss of DNA methylation or other inheritable modifications 
of chromatin [16]. We have recently developed an 
analytical approach able to identify stochastic epigenetic 
mutations (SEMs) not shared among subjects. We applied 
this peculiar analytical strategy to investigate the relations 
between stochastic epigenetic alterations and aging [15]. 
In the present study, we investigated the genome-wide 
DNA methylation profile in HCC, adjacent non-cancerous 
liver tissue and normal liver tissue. A new analytical 
approach has been adopted to identify epimutations 
potentially involved in the development of HCC.
RESULTS
Clinical and pathological characteristics of HCC 
patients
Clinical and pathological characteristics of enrolled 
HCC patients are described in Table 1. The mean age at 
HCC diagnosis was 65.9 ± 8.8 years. Most patients were 
male (76.8%) and positive for HCV (59.5%). Among 
the 69 HCC patients, 87% have pathologically defined 
cirrhosis and 85.6% have tumors grade II.
The complexity of variability of all the phenotypic 
traits has been reduced using Multiple Factor Analysis 
(Supplementary Figure 1). The first and second dimensions 
explained 18.29% and 16.63%, respectively, of the total 
variability of phenotypic traits.
Genome-wide methylation profiles in HCC tumor 
and adjacent non-cancerous tissues
A dimension reduction approach was used to 
visually inspect the dataset for signals in the methylation 
values. The Multi Dimensional Scaling Analysis was 
performed considering methylation signals from all CpG 
sites (Figure 1A) and in several genomic regions (tiling, 
genes, promoters and CpG Islands) (Figure 1B). This 
analysis showed a dramatic difference in methylation 
levels between HCC and peritumoral tissues. The Figure 2 
shows hierarchical clustering of samples based on the top 
1,000 CpG loci differentially methylated between HCC 
tumor and adjacent tissues. Excellent separation of tumor 
and peritumoral non-cancerous tissues was observed with 
only 3 misclassifications.
Paired differential methylation analysis between 
HCC vs peritumoral tissues was computed across the entire 
epigenome and selecting specific regions. The overall 
analysis identified 302,133 CpG sites out of 473,929 
across the entire epigenome that significantly differed 
in methylation levels. Among all significant CpG sites, 
36,615 probes resulted to have a delta greater than |0.30|. 
Differential methylation at the region level was computed 
based on a variety of metrix and combining methylation 
values inside tiling, genes, promoters and CpG Islands. 
Considering all the subgroups, the number of regions 
that resulted significantly different between the two sets 
and the number of the regions included in the array were: 
105,827 and 131,743 for tiling, respectively; 25,572 
and 29,592 for genes, respectively; 22,827 and 29,740 
for promoters, respectively; 17,534 and 25,837 for CpG 
islands, respectively. Mean DNA methylation differences 
are represented as a volcano plot in Figure 3. Scatterplots 
for differential methylation at site and regional levels are 
shown in Supplementary Figure 2.
These data indicate that aberrant DNA methylation 
in HCC is a very common event, covering the entire 
epigenome and mainly characterized by a loss of 
methylation in the tumor tissue. Considering that 
methylation differences between the two groups resulted 
extremely strong and involved the whole epigenome, a 
prioritization of significant results has been performed. 
The top 10 hypomethylated or hypermethylated genes 
extracted from this analysis and ranked by statistical 
significance are reported in Table 2.
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Stochastic epigenetic mutation analysis
For each sample, as described in the Material and 
Method section, the total number of SEMs was calculated 
using tissue from normal liver as reference. The number 
of SEMs resulted to be statistically significant higher in 
HCC (median: 77,370, IQR: 58,260–92,220) compared 
to adjacent non-cancerous tissue (median: 5,656, IQR: 
2,068–7,431, p = 1.8 × 10-11) and normal liver tissue 
extracted from healthy subjects (median: 1,308, IQR: 
854-2,148, p = 2 × 10-16) (Figure 4). Chromosomal 
distribution of SEMs in HCC samples and adjacent non-
cancerous tissue has been reported in Supplementary 
Figure 3.
Associations between SEMs and clinical and 
pathological characteristics
A multivariate regression analysis was performed in 
order to identify clinical and pathological traits potentially 
associated with SEMs. The number of SEMs identified 
in HCC and adjacent non-tumor tissue has been used 
as dependent variable, while specific phenotypic traits 
(viral infections, alcoholic liver disease, non-alcoholic 
Table 1: Clinical and pathological characteristics of 69 HCC patients
Variables Number of cases (%)
Age  
< 60 years 17 (24.6)
> 60 years 52 (75.4)
Gender  
Male 53 (76.8)
Female 16 (23.2)
Viral infection  
No Viral Infection 15 (21.8)
HBV 9 (13)
HCV 41 (59.5)
HBV and HCV 4 (5.7)
Alcoholic liver disease  
Yes 3 (4.4)
No 66 (95.6)
Non-alcoholic steatohepatitis  
Yes 8 (11.5)
No 61 (88.5)
Cirrhosis  
Yes 60 (87)
No 9 (13)
Child-Pugh class  
A 57 (82.6)
B 12 (17.4)
Tumor Grade  
I 3 (4.2)
II 59 (85.6)
III 7 (10.2)
Tumor Number  
1 49 (71)
2 11 (15.9)
3 4 (5.7)
4 5 (7.4)
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steatohepatitis, cirrhosis, Child-Pugh class, tumor grade, 
tumor number and Multiple Factor Analysis dimensions) 
have been adopted as independent variables. All the 
multiple regression models have been adjusted for age.
Viral infection resulted significantly associated 
to the number of SEMs observed in peritumoral 
tissue. In the multivariate regression hepatitis B virus 
(HBV), hepatitis C virus (HCV) and HBV+HCV 
infection status resulted independently associated to 
the number of SEMs observed in peritumoral tissue 
(p = 8 × 10-5, p = 0.002 and p = 0.027, respectively) 
and, less pronounced, in tumor (p = 0.032, 
p = 0.034 and p = 0.075, respectively). Figure 5 shows 
the number of SEMs observed in peritumoral tissue 
(Figure 5A) and in HCC tumor tissue (Figure 5B) 
according to the viral infection status.
Tumor grade resulted significantly associated to 
the number of SEMs observed in HCC tumor tissue (p 
= 0.02), but not in peritumoral tissue (p = 0.40). Figure 
6 shows the number of SEMs observed in peritumoral 
tissue (Figure 6A) and in HCC tumor tissue (Figure 6B) 
according to the tumor grade.
Complexity of clinical traits has been initially 
reduced using the Multiple Factor Analysis. The 
correlogram in Supplementary Figure 1 shows clinical 
traits associated to each dimension. The multiple 
regression analysis indicated that dimensions 1 (p = 
2 × 10-7) and 5 (p = 1.6 × 10-5) resulted associated to 
SEMs observed in HCC tumor, while only dimension 3 
(mainly collecting variability of age, HBV, HBV+HCV 
and non-alcoholic steatohepatitis) resulted significantly 
associated to the number of SEMs observed in HCC 
Table 2: Top 10 ranked hypomethylated or hypermethylated genes in HCC tumor tissue obtained 
after prioritization of all differentially methylated probes
Hypomethylated genes
Mean Methylation 
values
Gene Symbol Ensemble_ID Chromosome Start End Number of 
CpG sites
Peritumoral 
Tissue
Tumor 
Tissue
Delta Adjusted P Value
IGF1R ENSG00000140443 chr15 99192200 99507759 129 0.698 0.449 0.24 1.39E-22
HGF ENSG00000019991 chr7 81328322 81399754 9 0.433 0.237 0.19 1.66815E-17
HLA-DQA1 ENSG00000196735 chr6 32595956 32614839 8 0.583 0.341 0.24 1.49596E-19
PIK3CG ENSG00000105851 chr7 106505723 106547590 12 0.736 0.473 0.26 2.92839E-19
MAPK10 ENSG00000109339 chr4 86936276 87515284 40 0.638 0.449 0.18 1.14679E-19
KDR ENSG00000128052 chr4 55944644 55991756 9 0.392 0.270 0.12 5.39177E-13
FGFR1 ENSG00000077782 chr8 38268656 38326352 29 0.407 0.365 0.04 2.63192E-12
GNGT2 ENSG00000167083 chr17 47280153 47287936 11 0.587 0.388 0.19 3.49546E-17
PLCB4 ENSG00000101333 chr20 9049410 9461889 8 0.618 0.355 0.26 6.88013E-21
ADCY2 ENSG00000078295 chr5 7396321 7830194 29 0.667 0.363 0.30 9.6768E-27
Hypermethylated genes
Mean Methylation values
Gene Symbol Ensemble_ID Chromosome Start End Number of 
CpG sites
Peritumoral 
Tissue
Tumor 
Tissue
Delta Adjusted  
P Value
APC ENSG00000134982 chr5 112043195 112181936 25 0.307 0.596 −0.28 1.76369E-20
HIST1H4F ENSG00000198327 chr6 26240561 26240976 4 0.140 0.482 −0.34 1.50784E-24
FGF19 ENSG00000162344 chr11 69513000 69519410 19 0.194 0.434 −0.23 5.56857E-18
FZD1 ENSG00000157240 chr7 90893783 90898123 9 0.321 0.557 −0.23 7.55218E-26
LPAR2 ENSG00000064547 chr19 19734477 19739739 16 0.375 0.570 −0.19 3.69839E-17
HIST1H3F ENSG00000256316 chr6 26250370 26250835 4 0.101 0.442 −0.34 3.81087E-26
HIST1H3G ENSG00000256018 chr6 26271146 26271612 5 0.324 0.582 −0.25 9.95446E-23
HIST1H3J ENSG00000197153 chr6 27858093 27860884 7 0.263 0.534 −0.27 1.27291E-18
PMAIP1 ENSG00000141682 chr18 57567180 57571538 2 0.059 0.27 −0.22 3.79856E-16
RASGRF2 ENSG00000113319 chr5 80256491 80525975 30 0.696 0.712 −0.02 9.64807E-08
Oncotarget5www.impactjournals.com/oncotarget
Figure 2: Hierarchical cluster analysis. Hierarchical cluster analysis of the top 1000 significantly differentially methylated cpG sites 
between 69 pairs of HCC and adjacent non-cancerous liver tissues.
Figure 1: Exploratory analysis of methylation data. Dimension reduction obtained by Multi Dimensional Scaling (MDS) is used 
to visually resume the complexity of methylation profile in HCC and peritumoral tissues at site level (A) and at regional level (B). Plots 
have been obtained using the first two dimensions.
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tumor and peritumoral tissues (p = 0.0003 and p = 0.015, 
respectively). 
For other phenotypic traits the associations with the 
number of SEMs were not significant.
SEMs annotation analysis and candidate 
markers
Number of SEMs has been calculated for all samples. 
We identified 109,174 and 14,315 different SEMs in 
HCC tumor and adjacent non-tumor tissues, respectively. 
Among them 101,921 SEMs resulted present only in 
HCC and absent in adjacent non-cancerous tissues. We 
annotated genomic position of SEMs discovered in each 
sample and selected SEMs that were present in more than 
90% of HCC samples and never present in adjacent non-
cancerous tissues. Through this procedure a list of 4 genes 
(Table 3) was identified: Adherens Junctions Associated 
Protein 1 (AJAP1), Adenosine Deaminase RNA Specific 
B2 (ADARB2), Protein Tyrosine Phosphatase Receptor 
Type N2 (PTPRN2) and Sidekick Cell Adhesion Molecule 
1 (SDK1). 
DISCUSSION
DNA methylation is the main epigenetic 
mechanism adopted by cells to regulate gene expression, 
and alterations of this mechanism are involved in the 
pathogenesis of cancer. In this paper, we studied DNA 
methylation aberrations in HCC through the Illumina 
450K DNA methylation array and adopting an innovative 
analysis devoted to the identification of epimutations.
Figure 3: Differential methylation analysis of Illumina 450K data. Volcano plot showing differential methylation analysis of 
69 paired HCC tumor and adjacent non-cancerous liver tissues at site level (A) and at regional level (B). The x-axis represents the mean 
DNA methylation difference (adjacent non-cancerous liver tissue – HCC), while the y-axis shows the – log10 of the p value for each CpG 
site (A) or genomic region (B). 
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We characterized DNA methylation profiles in 
paired HCC tumor and adjacent non-cancerous liver 
tissue samples from 69 patients. Visual inspection of DNA 
methylation levels, obtained through multi-dimensional 
scaling, revealed a marked difference between HCC tumor 
and peritumoral tissues. Also the differential methylation 
analysis confirmed substantial changes of DNA methylation 
mainly due to loss of methylation in HCC.
Nishida et al. [17] compared DNA-methylation 
profile extracted from 59 HCC with that from 58 adjacent 
non-cancerous liver tissues, using HumanMethylation450 
BeadChip array. They identified 38,330 CpG sites 
differentially methylated with an effect greater than 
15% between both groups of samples, of which 92% 
and 8% were respectively hypomethylated (mainly 
located within intergenic regions) and hypermethylated 
(predominantly observed within promoter regions and 
CpG islands) in HCC. A significant association between 
methylation profile and tumor size has been detected, 
particularly in HCV-positive patients. A predominant DNA 
hypomethylation in HCC has been also reported by several 
other studies and a specific subset of CpG sites correlated 
with HCV infection and liver cirrhosis [10–13] . 
In the present study we confirmed that HCC and 
adjacent non-cancerous tissues have a different epigenetic 
profile, indeed the number of differentially methylated 
probes resulted extremely high (n=302,133). In this 
condition it is difficult to identify candidate epigenetic 
signatures and to highlight specific biological pathways 
and functions, considering that epigenetic deregulation 
is widespread throughout the genome. Several studies 
selected the top hypermethylated or hypomethylated 
genes on the basis of p value or effect size [10–13]. 
However it has to be considered that the identification of 
best associations, based only on deserving of statistical 
thresholds, may lead to inconclusive or biased results. 
On reviewing the literature, we identified four studies 
[10–13] that explored genome-wide DNA methylation 
profiles in HCC tumor and adjacent non-tumor tissues 
through Illumina’s 450K or 27K arrays and published a 
list of the top differentially methylated CpG sites. A total 
number of 161 probes resulted combining the lists from 
these four studies (Supplementary Table 1). Although, all 
these probes have been confirmed in the present study with 
a similar trend, only 8 probes have been reported by at 
least 2 out of 4 selected studies. This poor overlap suggests 
that the selection of candidate markers obtained by fixing 
arbitrary statistical thresholds might produce biased results. 
In our study, we used an alternative approach to 
identify epigenetic markers, based on epigenetic mutations 
analysis, as previously applied in the field of aging [15]. 
In each sample, SEMs have been identified using normal 
Figure 4: Exploration of SEMs in HCC. Box Plots show distribution of SEMs number in normal, peritumoral and HCC tumor 
tissues.
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liver tissue methylation data as reference population. 
We have previously reported that the number of SEMs 
increases exponentially with age, and for this reason all 
analyses have been adjusted, considering age as covariate. 
Interestingly, we observed a progressive increase in the 
number of SEMs from normal liver, peritumoral tissue 
(predominantly with chronic hepatitis/cirrhosis) to HCC 
tissue. In HCC the median number of SEMs resulted 13 
times higher than in adjacent non-cancerous liver tissue. 
Moreover the number of SEMs observed in peritumoral 
tissues was 4-fold higher than that identified in normal 
liver tissues obtained from healthy subjects. The number 
of SEMs observed in peritumoral and tumoral tissues 
resulted also significantly higher in samples with HBV 
and HCV viral infection. Both HBV and HCV infections 
have a main role in the development of HCC through 
genetic and epigenetic alterations. It has been reported 
that aberrant DNA methylation may be induced by direct 
viral activity or indirectly through related chronic liver 
inflammation [18]. In addition, it is well known that 
viral infection is able to affect DNA methyl transferase 
expression in HCC [19]. 
We also focused the attention on other clinical-
phenotypic traits and we observed that the number of 
SEMs detected in HCC tissue increased progressively 
with histopathological tumor grade, suggesting that 
tumor progression and aggressiveness correlate with the 
accumulation of epigenetic alterations. This represents an 
interesting finding, supporting the potential use of SEMs 
number as a prognostic marker in HCC. 
Therefore, the extreme heterogeneity and complexity 
among HCC epigenomes makes difficult to identify 
specific epigenetic profiles associated to phenotypic traits. 
While, the number of SEMs emerged as a new variable 
with high sensitivity and potentially able to summarize the 
degree of epigenetic alterations with a simple score.
In order to identify novel candidate potential 
epidrivers, after the calculation of SEMs,  we analysed 
genomic position of SEMs discovered in each sample. 
We performed this analysis both for HCC and peritumoral 
tissues. We identified a list of SEMs that were present 
in more than 90% of HCC samples and never present 
in peritumoral tissues. Four genes emerged from this 
analysis: AJAP1, ADARB2, PTPRN2, SDK1. These 
epimutations were characterized by hypermethylation at 
promoters level and concomitant hypomethylation at gene 
body level in HCC tumor tissues (Table 3). Interestingly, 
a similar epigenetic signature for AJAP1, ADARB2 and 
Table 3: List of genes epimutated in more than 90% of HCC samples and never found in peritumoral 
tissues
Gene 
Symbol
Ensemble_ID Chr Start End
Promoter Mean 
Methylation 
Level Normal 
Liver Tissue
Promoter Mean 
Methylation Level 
Peritumoral Tissue
Promoter Mean 
Methylation Level 
Tumoral Tissue
Gene Body Mean 
Methylation 
Level Normal 
Liver Tissue
Gene Body Mean 
Methylation Level 
Peritumoral Tissue
Gene Body Mean 
Methylation 
Level Tumoral 
Tissue
AJAP1 ENSG00000196581 chr1 4714792 4852594 0.12 0.11 0.28 0.6 0.65 0.37
ADARB2 ENSG000000185736 chr10 1228073 1779670 0.08 0.08 0.12 0.72 0.75 0.41
PTPRN2 ENSG00000155093 chr7 157331750 158380480 0.25 0.28 0.45 0.8 0.77 0.43
SDK1 ENSG00000146555 chr7 3341080 4308632 0.12 0.1 0.36 0.85 0.81 0.49
Figure 5: Number of SEMs is associated to viral infection. Box Plots show distribution of SEMs in peritumoral tissue (A) and 
HCC tumor tissue (B) in relation to the HBV/HCV infection status.
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PTPRN2 has been previously reported in glioblastoma 
[20–21]. Unfortunately, it was not possible using 
microarray-based method to understand if these epigenetic 
alterations were allele-specific.
AJAP1 is a component of adherent junctions. 
It interacts with E-cadherin–β-catenin complexes in 
polarized epithelial cells. The methylation of AJAP1 
may lead to the release of β-catenin and the activation 
of Wnt signaling [22]. AJAP1 expression has been 
recently reported to be reduced in HCC compared with 
non-cancerous liver tissues and to be associated with 
hypermethylation of the AJAP1 promoter. Indeed, 
suppression of AJAP1 expression may represent a specific 
event that occurs in the final stage of the initiation of HCC 
[23]. Several evidences concerning the role of AJAP1 as 
a putative tumor suppressor genes regulated by promoter 
hypermethylation have been reported in cervical cancer, 
esophageal squamous cell carcinoma and gastric cancer 
[22, 24, 25]. In addition, it has been shown that AJAP1 
expression was drastically reduced in glioblastoma tumors, 
and the loss of expression correlated with AJAP1 promoter 
hypermethylation and poorer survival. Interestingly, 
restoration of AJAP1 gene expression by transfection or 
demethylating agents decreased tumor cell proliferation 
and migration in glioblastoma cell lines [26].
ADARB2 encodes a member of the double-stranded 
RNA adenosine deaminase family of RNA-editing 
enzymes and plays a regulatory role in RNA editing. 
This may affect gene expression and function through 
the modulation of: mRNA translation, by changing 
codons and hence the amino acid sequence of proteins; 
pre-mRNA splicing, by altering splice site recognition 
sequences; RNA stability, by changing sequences involved 
in nuclease recognition; genetic stability in the case of 
RNA virus genomes, by changing sequences during 
viral RNA replication; and RNA structure-dependent 
activities, such as microRNA production or targeting or 
protein-RNA interactions [21]. The gene body region of 
ADARB2 resulted extremely hypomethylated in HCC 
tumor compared to adjacent tissues. Currently there are no 
data available concerning the potential role of ADARB2 
in the development of HCC. However, a growing body of 
evidence indicates an important role of adenosine to inosine 
RNA editing, modulated through epigenetic mechanisms, 
in the pathogenesis and progression of cancer [21, 27]: 1) 
hypomethylation of ADARB2 has been reported as a marker 
of relapse in pediatric acute lymphoblastic leukemia; 2) 
RNA levels of the three ADAR family members (ADAR, 
ADARB1, and ADARB2) were significantly reduced in 
brain tumors, the reduction of ADARB2 correlated with 
Figure 6: Number of SEMs is associated to tumor grade. Box Plots showing distribution of SEMs in peritumoral tissue (A) and 
tumoral tissue (B) in relation to the tumor grade.
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the grade of malignancy of glioblastoma multiforme, the 
most aggressive of brain tumors, displaying a 99% decrease 
in ADARB2 RNA levels; 3) overexpression of ADAR and 
ADARB1 (an important paralog of ADARB2) in the U87 
glioblastoma multiforme cell line significantly decreased 
proliferation rate.
PTPRN2 belongs to the protein tyrosine phosphatase 
family, it has an important role in vesicle-mediated 
secretory processes and exhibits a phosphatidylinositol 
phosphatase against phosphatidylinositol 4,5-diphosphate 
and phosphatidylinositol 3-phosphate  [28]. PTPRN2 
has been reported to be significant hypermethylated 
in squamous cell lung cancer and glioblastoma 
[20, 29]. PTPRN2 resulted in the top list of marker down 
methylated in HCC, as reported by Shen et al [10], and 
similarly to our results the hypomethylation of this gene 
was restricted to the gene body region. 
SDK1 gene codes for a cell adhesion molecule 
with a potential role in cancer progression. This gene is 
responsive to androgens, resulted overexpressed and able 
to regulate cellular migration in prostate cancer [30]. 
Moreover, in whole-exome sequencing studies performed 
on adrenocortical carcinoma, this gene was affected 
by somatic mutations [31]. However, to the best of our 
knowledge there are not data regarding the role of this 
gene in the pathogenesis of HCC.
In summary, we confirmed that HCC showed a 
methylation profile completely deregulated and very far 
from adjacent non-cancerous liver tissues. An alternative 
genome-wide DNA methylation analytical approach, 
based on the identification of epimutations, represents the 
real novelty of this study. This statistical approach resulted 
a robust method to appreciate epigenetic variability 
among samples. Indeed, the number of SEMs observed in 
HCC tissue was strongly associated to several important 
phenotypic traits. In addition, this analysis allowed the 
identification of four epigenetically regulated candidate 
genes (AJAP1, ADARB2, PTPRN2, SDK1), potentially 
involved in the hepatocarcinogenesis. Future studies are 
required to further validate the differential expression of 
these genes at the RNA or protein level in HCC.
MATERIALS AND METHODS
Samples, patients and phenotypes
Paired HCC tumor and adjacent non-cancerous liver 
tissue samples were obtained from 69 patients (16 females, 
53 males) who underwent surgical resection from 2008 to 
2015 at the National Cancer Institute of Naples. Samples 
were frozen immediately after surgical removal and stored 
at –80°C until DNA extraction. Demographic data (age and 
gender), information on viral infection (HBV and HCV), 
clinical and pathological characteristics (alcoholic liver 
disease, non-alcoholic steatohepatitis, cirrhosis, Child-
Pugh class, tumor grade and tumor number) were obtained 
from the medical records. Written informed consent was 
obtained from all patients. This study was approved by 
the Ethics Committee of the Istituto Auxologico Italiano.
DNA preparation and infinium methylation 
450K assay
DNA was extracted using the QIAamp DNA 
Mini kit (Qiagen GmbH,D-40724 Hilden, Germany), 
according to the manufacturer’s instructions. Bisulfite 
modification of 1 μg DNA was conducted using an EZ 
DNA Methylation Kit (Zymo Research) according to 
the manufacturer’s procedure. The Infinium Methylation 
450K assay was performed according to Illumina’s 
standard protocol. Six HCC/adjacent non-tumor tissue 
pairs were processed on the same chip to avoid chip-to-
chip variation. Quality control and quantification of DNA 
were performed before and after bisulfite conversion.
450k methylation data and populations 
description
Methylation data analysed in the study were 
obtained from different datasets: 1. The Case Population: 
69 HCC tumor tissues. 2. The Control Population: 69 
paired adjacent non-cancerous liver tissue samples. 3. 
The Reference Population: Methylation raw data from 
47 liver biopsies from healthy heart-beating and brain 
death donors with an age spanning from 13 to 90 years 
[32] were obtained from the Istituto Auxologico Italiano 
Epigenetic Database. Donors were free from known viral 
hepatitis and liver cirrhosis. Methylation row data from 
67 normal liver tissues were obtained from the public 
functional genomics data repository GEO. We selected 
one dataset containing methylation idat files classified as 
normal liver tissue (GSE61446). Using these two datasets 
we obtained a unique reference containing 114 subjects. 
This population represented the reference population used 
for the estimation of epigenetic mutations.
Data management, pre-processing, normalisation 
and quality control
Illumina Methylation 450K raw data were analysed 
using the RnBeads analysis software package [29]. 
Sites overlapping SNPs were firstly removed from the 
analysis (n = 4713) as well as probes on sex chromosomes 
(n = 11119). Probes and samples of highest impurity were 
removed from the dataset using the Greedycut algorithm 
provided in the RnBeads package. We have considered 
every β value to be unreliable when its corresponding 
detection p-value was not below the threshold (T = 0.05). 
The background was subtracted using the methylumi 
package (method “noob”) [33]. The signal intensity 
values were normalized using the SWAN normalization 
method, as implemented in the minfi package. In addition 
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to CpG sites, 4 sets of genomic regions were covered in 
the analysis (tailing, genes, promoters and CpG Islands).
Differential methylation analysis and 
prioritization analysis
Paired Differential methylation analysis was 
conducted both at site and region level according to the 
sample groups. P-values were computed using the limma 
method for the site level analysis, while a combined 
p-value was calculated from all site p-values for the 
region-based analysis [33]. After this analysis results have 
been ordered depending on their relevance on HCC field. 
Lists of hypermethylated and hypomethylated genes have 
been prioritized using the Phenolyzer on line tool (http://
phenolyzer.usc.edu/) and using “HEPATOCELLULAR 
CARCINOMA” and “HEPATIC” as key word.
Epimutation detection
In both HCC and adjacent liver tissue samples SEMs 
were identified, as previously described [15]. Briefly, after 
the pre-processing step, for all probes, the distribution and 
variability of methylation levels were studied using box 
and whiskers plots. Methylation levels of each sample 
were compared to those of normal liver tissues from a 
reference population. The same approach was applied also 
for each subject of the reference population. One by one 
each subject of the reference population was extracted and 
compared to the remaining N-1 subjects. At each locus, 
whenever the methylation level of one sample differed 
extremely from the rest of the population this outlier 
was considered as epimutated. Thus, for each locus, 
epimutated samples were identified as the extreme outliers 
when their methylation levels lay outside of Q1-(3 x IQR) 
and Q3+(3 x IQR). Finally, all epimutated loci were 
annotated in a new data matrix that allowed to calculate, 
for each sample, the total amount of epimutations and their 
genomic position. The box and whiskers plot analysis was 
conducted using boxplot function in the R car package 
and confirmed using the outlier function in the R outliers 
package. A validation of this analytical approach has been 
previously reported [15].
Statistical analysis
The “Shapiro.test” function provided in the R 
package “stats” was applied to test normality among 
variables. The “Wilcox.test” function provided in the 
R package “class” was used to test differences between 
cases and controls groups for all non-parametric data. 
Considering the presence of categorical variables, the 
Multiple Factor Analysis was performed using the Multiple 
Factor Analysis of mixt data approach and the “FAMD” 
function provided in the R package “FactoMineR”. 
The univariate and multivariate linear regressions were 
conducted using the “Generalised Linear Model” function 
provided in the R “base” package. Bonferroni’s correction 
was performed to correct for multiple testing.
Abbreviations 
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